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A B S T R A C T
Background: Preterm birth (PTB) is a leading cause of perinatal morbidity and mortality. Interventions
aimed at preventing PTB can be classiﬁed as primary, secondary, or tertiary prevention.
Objective: To conduct a review of systematic reviews on the effectiveness and safety of primary and
secondary preterm birth prevention interventions.
Search strategy: A systematic literature search of the Cochrane, PubMed/Medline, EMBASE and CINAHL
databases was conducted on 2 September 2015, and updated on 21 November 2016.
Selection criteria: We included any published systematic review of randomized controlled trials (RCTs) or
individual patient data (IPD) of RCTs related to primary or secondary prevention of PTB, published
between 2005–2016 where gestational age at birth (of any interval) was a pre-speciﬁed outcome.
Individual trials and non-systematic reviews were not eligible.
Data collection and analysis: The population of interest was all pregnant women, regardless of PTB risk.
The primary outcome was PTB < 37 weeks.
Main Results: In total, 112 reviews were included in this study. Overall there were 49 Cochrane and 63
non-Cochrane reviews. Eight were individual participant data (IPD) reviews. Sixty reviews assessed the
effect of primary prevention interventions on risk of PTB. Positive effects were reported for lifestyle and
behavioural changes (including diet and exercise); nutritional supplements (including calcium and zinc
supplementation); nutritional education; screening for lower genital tract infections. Eighty-three
systematic reviews were identiﬁed relating to secondary PTB prevention interventions. Positive effects
were found for low dose aspirin among women at risk of preeclampsia; clindamycin for treatment of
bacterial vaginosis; treatment of vaginal candidiasis; progesterone in women with prior spontaneous PTB
and in those with short midtrimester cervical length; L-arginine in women at risk for preeclampsia;
levothyroxine among women with tyroid disease; calcium supplementation in women at risk of
hypertensive disorders; smoking cessation; cervical length screening in women with history of PTB with
placement of cerclage in those with short cervix; cervical pessary in singleton gestations with short
cervix; and treatment of periodontal disease.
Conclusion: The overview serves as a guide to current evidence relevant to PTB prevention. Only a few
interventions have been demononstrated to be effective, including cerclage, progesterone, low dose
aspirin, and lifestyle and behavioural changes. For several of the interventions evaluated, there was
insufﬁcient evidence to assess whether they were effective or not.
© 2019 Elsevier B.V. All rights reserved.
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An estimated 11% of live births were born preterm, equating to
nearly 15 million preterm babies born in 2014 [23]. Of the 38
countries with high-quality data, preterm birth rates have
increased since 2000 in 26 countries. Complications of PTB were
the leading cause of death in children under ﬁve years of age
globally in 2016, accounting for approximately 16% of all deaths,
and 35% of deaths among newborns [1]. In general, preterm-
associated neonatal and child survival rates are much poorer in
low- and middle-income countries [1–3].
Interventions aimed at preventing PTB can be classiﬁed as
primary (i.e. directed at all women, including populations of
women at higher- or –lower-risk of PTB), secondary (i.e. directed at
a sub-group of women with known or identiﬁed risk factor/s), or
tertiary prevention (interventions used after preterm labor (PTL)
has commenced) [4]. Primary and secondary prevention includes a
wide range of interventions, including pharmacological treat-
ments, such as low-dose aspirin [5] or progesterone [6–9];
nutritional interventions [10]; surgical procedures, such as cervical
cerclage [11,12]; devices, such as cervical pessary [13–15]; as well
as more complex, population-level or health system-level inter-
ventions, such as dietary education and screening and treatment
programmes [16].
In 2015, a review of systematic reviews on primary and
secondary preterm birth (PTB) interventions was initiated with
two main objectives:
1) to systematically assess existing literature regarding
effectiveness and safety of interventions to prevent PTB; and 2)
to prioritize interventions for further research in low- and middle-
income country settings. Reviews of systematic reviews on PTB
prevention have been conducted previously (2014).(16) However,
these have focused only on Cochrane reviews. There is an
increasing number of high-quality systematic reviews of random-
ized controlled trials (RCTs) on PTB prevention published in other
journals. Furthermore, a number of important reviews have been
published or updated in the past ﬁve years, including several
individual patient data (IPD) meta-analyses.
In this paper, we present the ﬁndings of the review of
systematic reviews of primary and secondary PTB prevention
interventions, as well as a review of planned and ongoing RCTs.
Methods
This review of systematic reviews was conducted according to
standards of the Cochrane Handbook of Systematic Reviews of
Interventions [17], and reported according to the PRISMA Check-
list [18]. The review was registered with the PROSPERO Interna-
tional Prospective Register of Systematic Reviews (CRD42015
027440).Please cite this article in press as: A. Matei, et al., Primary and seconda
ongoing randomized controlled trials, Eur J Obstet Gynecol (2019), httpEligibility criteria
We included any published systematic review or IPD of RCTs
related to primary or secondary PTB prevention published between
January 2005 to October 2016 where gestational age at birth (of any
interval) was a pre-speciﬁed outcome. Individual trials and non-
systematic reviews were excluded. Systematic reviews of non-
randomized studies were also excluded.
We deﬁned a systematic review as reviews that: had a clear
research question, described a comprehensive literature search
(including at least two databases), used a duplicated study
selection and data extraction process, and described the character-
istics of the included studies. The population of interest was all
pregnant women, regardless of PTB risk, including women with
singleton or multiple pregnancies, without clinically conﬁrmed
preterm labor (PTL). Interventions of any type, at any level of the
health system (facility, health system, and health policy) were
eligible. Reviews of pre-conception, tertiary prevention or
postpartum/postnatal interventions were excluded. In order to
maximize inclusiveness, systematic reviews of interventions that
may have an indirect effect on PTB (i.e. interventions aimed at
other conditions in pregnancy, but potentially also affecting PTB)
were also eligible. If the review included both RCTs and non-RCTs,
we included the review if results from RCTs only were reported
separately. Where two or more reviews addressed the same
research question, we included all reviews. However, where a
systematic review had been speciﬁcally updated, we included only
the most recent version.
Literature search, screening and extraction
A systematic literature search of the Cochrane, PubMed/
Medline, EMBASE and CINAHL databases was conducted on 2nd
September 2015, and updated on 21st November 2016. As the
publications of interest are high-quality systematic reviews, grey
literature sources were not included (search strategy provided in
Supplementary material). All citations were downloaded into a
reference manager and duplicate citations removed. Two authors
independently screened titles and abstracts of each citation, and
included those for full text review (according to criteria deﬁned
above). Each retrieved full text article was independently
evaluated for inclusion by two authors. We developed and pre-
tested a data extraction form, capturing review characteristics and
outcome data for comparisons of interest. Where the GRADE
criteria [19] were used for our primary outcome (i.e. PTB < 37
weeks), the certainty of evidence was extracted. Any differences
during screening and extraction were resolved through discussion
and/or consultation with a third author. Two authors indepen-
dently also assessed the methodological quality of the included
reviews using the AMSTAR tool [20].ry prevention of preterm birth: a review of systematic reviews and
s://doi.org/10.1016/j.ejogrb.2018.12.022
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Clinical Trials Registry Platform (ICTRP) on 15th November 2016.
ICTRP aggregates 17 national and international trial registries
(including Clinicaltrials.gov, the EU Clinical Trials Register and the
Pan African Clinical Trials Registry), providing a single, regularly
updated search portal for all registered trials. We used a keyword
search in ICTRP (using “premature” or “preterm birth” or
“prematurity”) to identify any RCTs of primary or secondary PTB
prevention interventions with date of registration from 1st January,
2005 to 31st December, 2016. We extracted characteristics of any
eligible registered RCTs. Identiﬁed trials were reviewed indepen-
dently for inclusion by two authors, and classiﬁed by type of
intervention.
Outcomes
Primary and secondary outcomes were pre-deﬁned before data
extraction. Selection of outcomes was informed by ﬁndings of the
COPOP project on core outcomes for PTB prevention [21]. as well as
critical outcomes used in the WHO antenatal care recommendations
for a positive pregnancy experience [22]. The primary outcome wasFig. 1. Flow chart for search and identiﬁcation of
Please cite this article in press as: A. Matei, et al., Primary and seconda
ongoing randomized controlled trials, Eur J Obstet Gynecol (2019), httpPTB < 37 weeks. The secondary outcomes were PTB < 34, <32, and
<28 weeks (or any other reported GA threshold), maternal
satisfaction, and neonatal outcomes including low birth weight
(LBW) (i.e. birth weight <2500 g), admission to neonatal intensive
care unit (NICU), fetal mortality (i.e. fetal death after 20 weeks),
neonatal mortality (as deﬁned by the trials) and perinatal death (i.e.
either fetal mortality or neonatal mortality).
Our review protocol pre-speciﬁed several other maternal and
neonatal morbidity outcomes (Prospero registration number
CRD42015027440). However, during piloting of data extraction
we found the secondary outcome list to be unmanageably large.
The group agreed through consensus to reduce the list, considering
what data were likely to be available.
Classiﬁcation, analysis and reporting
We aimed to classify all identiﬁed interventions as either
primary or secondary prevention interventions, or both. Analysis
and reporting was primarily descriptive, presenting the identiﬁed
interventions and the magnitude of effect on primary and
secondary outcomes. studies in the review of systematic reviews.
ry prevention of preterm birth: a review of systematic reviews and
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Study selection
The initial search identiﬁed 1,372 unique citations; 132 were
included for full text review. An updated search was run in
November 2016, which identiﬁed an additional 300 citations,
yielding 40 for full text review. Of the 172 full text articles
reviewed, 72 were excluded. An additional 12 papers were added,
as they were the latest version of a published review. In total, 112
reviews were included (Fig. 1).
An overview of types of interventions identiﬁed is shown in
Table 1. Classiﬁcation of the included reviews according to types of
interventions is shown in Supplementary material. Table 2 shows
the results of searching the ICTRP trial database. Overall 172
registered trials were found, 47 on primary PTB prevention and 125
on secondary PTB prevention. Most of the trials evaluated the
effect of different drugs, mostly aspirin and progesterone. Twenty
four trials evaluated beneﬁts of nutritional supplementation in
prevention of PTB. Of them, eight were on antenatal supplemen-
tation of polyunsaturated fatty acids.
Supplementary material shows the descriptive characteristics
of included systematic reviews. Overall there were 49 Cochrane
and 63 non-Cochrane reviews. Eight were IPD reviews. The
publication date of the trials included in the reviews ranged from
1953 to 2016. The number of included trials in each review ranged
from 0 to 86. Only 38 reviews used the GRADE criteria. Figs. 2 and 3
show the effect estimates of primary (Fig. 2) and secondary (Fig. 3)
prevention intervention on PTB < 37 weeks.
Intervention effects on primary outcome (preterm birth<37 weeks)
I Primary prevention of preterm birth
Sixty reviews assessed the effect of primary prevention
strategies on risk of PTB (Fig. 2). For many interventions, there
were multiple, overlapping systematic reviews.
1 Medications: Thinkhamrop (2015) compared use of antenatal
prophylactic antibiotics with placebo among women (lowor
high risk of PTB) (5 trials, 1480 women) and showed no effect
on risk of PTB (RR 0.85, 95% CI 0.64–1.14).Table 1
Overview of types of interventions identiﬁed.
Drug 
Device 
Psychosocial 
Surgical/procedural 
Nutritional supplementation or treatment 
Lifestyle or behavioural 
Screening +/- treatment
(use of investigations, examinations or special tests,
which may or may not prompt the use of certain interventions)
Health system 
Please cite this article in press as: A. Matei, et al., Primary and seconda
ongoing randomized controlled trials, Eur J Obstet Gynecol (2019), http2 Models of care: Two reviews evaluated models of health care.
Catling et al. (2015) conducted a Cochrane review of four trials
and 2350 women enrolled in group antenatal care compared
to standard care. There was a marginal difference in risk of
PTB (RR 0.75, 95% CI 0.57–1.00, moderate-quality evidence).
Fernandez Turienzo et al. (2016) meta-analysed 15 trials of
22,437 women randomized to alternate models of antenatal
care (compared to standard care). This included “midwife-led
continuity models of care, PTB prevention programmes,
clinic-based specialised care and stand-alone interventions
involving the provision of health or social care delivered in
conjunction with standard antenatal care”. They found a
statistically signiﬁcant decrease in risk of PTB < 37 weeks in
women receiving alternate models of care (RR 0.84, 95% CI
0.74–0.96). The authors identiﬁed signiﬁcant heterogeneity
among trials.
3 Lifestyle and behavioural changes: Diet and/or interventions
targeted at increasing physical activity were evaluated in four
reviews. Bain et al. (2015) compared diet and exercise advice
with no advice in an unselected group of pregnant women (5
trials, 2,713 women). Their primary interest was prevention
of excessive weight gain in pregnancy. The risk of PTB was
reduced among women enrolled in diet and exercise (RR 0.71,
95% CI 0.55–0.93). This ﬁnding was not replicated in other
systematic reviews, although intervention deﬁnitions were
somewhat different.
Benja et al. (2015) conducted a Cochrane review on the effect
of diet and exercise advice compared to no advice in an
unselected group of women in preventing gestational
diabetes mellitus (GDM) (16 trials, 5923 women). They
found no difference in risk of PTB (RR 0.91, 95% CI 0.68–1.22),
however eligible studies were those that related to address-
ing GDM risk as opposed to gestational weight gain.
Thangaratinam et al. (2012) compared any dietary or
lifestyle intervention to standard care among a group of
unselected pregnant women, including women with GDM or
obesity. They identiﬁed no effects on PTB risk (13 trials, 2652
women, RR 0.78, 95% CI 0.60–1.02), nor when stratiﬁed
based on intervention (dietary advice, physical activity, or
both).Primary prevention Secondary prevention
Antiplatelet
Antibiotics
Antiplatelet
Antibiotics
Progestogens
Other
– Pessary
Telephone support Support for smoking cessation
– Cerclage
Dental treatment
Mode of delivery
Calcium
Iron +/- folic acid
Polyunsaturated fatty acids
Vitamins (A,B6,B12,C,D,E)
Zinc
Multiple micronutrients
Antioxidants
Probiotics
Other
Iron +/- folic acid
Polyunsaturated fatty acids
Vitamins (A)
Other
Diet
Exercise
Bed rest
Activity restriction
Screening whole population Screening a selected sub-group only
Alternative model of care –
ry prevention of preterm birth: a review of systematic reviews and
s://doi.org/10.1016/j.ejogrb.2018.12.022
Table 2
Results of searching ICTRP trial database (N = 172).
Primary prevention
(N = 47)
Secondary prevention
(n = 125)
Drug (n = 71) Antiplatelet - 1
Antibiotics – 1
Other – 1
Antiplatelet - 2
Antibiotics - 7
Progestogens - 51
Other – 8
Device (n = 21) Pessary – 21
Psychosocial (n = 1) 1 0
Surgical/procedural
(n = 15)
0 Cerclage - 11
Dental treatment - 1
Mode of delivery - 3
Nutritional supplementation or treatment (n = 24) Iron +/- folic acid - 1
Polyunsaturated fatty acids - 7
Vitamins - 3
Multiple micronutrients - 3
Probiotics - 3
Other – 3
Polyunsaturated fatty acids - 1
Zinc - 1
Probiotics - 2
Lifestyle or behavioural (n = 8) 6 2
Screening +/- treatment (n = 14) 9 5
Health system (n = 6) 5 1
Multiple (n = 12) 3 9
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increased exercise in sedentary women and decreased
exercise in ﬁt women (they did not include dietary
interventions). There was no effect on PTB with increased
exercise among sedentary women (3 trials, 111 women, RR
1.82, 95% CI 0.35–9.57) or with reduction in exercise amongFig. 2. Effect estimates of primary preve
Please cite this article in press as: A. Matei, et al., Primary and seconda
ongoing randomized controlled trials, Eur J Obstet Gynecol (2019), httpphysically ﬁt women (1 trial, 61 women, RR 1.18, 95% CI 0.08–
17.99).
4 Nutritional supplementation: Nutritional supplementation
interventions were evaluated in 34 systematic reviews.
Calcium supplementation was evaluated in ﬁve reviews.
Calcium of any dose was evaluated by Imdad et al. (2011) in antion intervention on preterm birth.
ry prevention of preterm birth: a review of systematic reviews and
s://doi.org/10.1016/j.ejogrb.2018.12.022
Fig. 2. (Continued)
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disorders of pregnancy (5 trials, 9919 women). Calcium (of
any dose) initiated prior to 32 weeks gestation was found to
reduce risk of PTB (RR 0.88, 95% CI 0.78–0.99) when
compared to placebo or no supplementation. Hofmeyr
et al. (2014) also evaluated the effects of calcium supplemen-
tation for prevention of hypertensive disorders (11 trials,
15,275 women), and showed a decrease in PTB risk with high
dose calcium >1 g/day administered to all pregnant women
(RR 0.76, 95% CI 0.60 to 0.97, high-quality evidence).
The Cochrane review by Buppasiri et al. (2015) evaluated the
role of calcium supplementation in improving obstetricalPlease cite this article in press as: A. Matei, et al., Primary and seconda
ongoing randomized controlled trials, Eur J Obstet Gynecol (2019), httpoutcomes other than hypertensive disorders. The risk of PTB
was not reduced with calcium supplementation compared to
placebo or no supplementation, (13 trials, 16139 women RR
0.86, 95% CI 0.70–1.05). However, high dose (>1 g/day) but not
low dose (<1 g/day) calcium supplementation was associated
with a reduction in risk of PTB (RR 0.81, 95% CI 0.66 to 0.99).
Iron supplementation was evaluated in four reviews. Daily
iron supplementation with iron alone or in combination with
folic acid or other minerals or vitamins was found to reduce
PTB < 34 weeks when compared to placebo, no treatment, or
an equivalent non-iron supplement (RR 0.51, 95% CI 0.29 to
0.91), but the risk of PTB < 37 weeks was not signiﬁcantlyry prevention of preterm birth: a review of systematic reviews and
s://doi.org/10.1016/j.ejogrb.2018.12.022
Fig. 2. (Continued)
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(Pena Rosa et al., 2015a). In a separate review assessing
intermittent iron supplementation, the risk of PTB < 37 weeks
or <34 weeks was not reduced (Pena Rosa et al., 2015b).
Haider et al., (2013) identiﬁed 12 trials (unspeciﬁed number
of women) that evaluated the effect on PTB < 37 weeks with
iron supplementation, alone or in combination with folic acid.
There was no signiﬁcant effect on PTB (RR 0.84, 95% CI 0.68–
1.03). Cantor et al. (2015), using a different timeframe and
different databases, compared routine iron supplementation
to an unspeciﬁced placebo. They identiﬁed two trials (1010
women) and no signiﬁcant effect on PTB (RR 0.88, 95% CI
0.55–1.42).
Folic acid supplementation was evaluated in two reviews.
Saccone and Berghella (2016) compared folic acid supple-
mentation to placebo or no treatment and identiﬁed one trial
(1654 women). In this trial, there was no signiﬁcant effect on
PTB (RR 0.99, 95% CI 0.82–1.18). Lassi Zohra et al. (2013)
evaluated folic acid with or without other supplements
compared to placebo or non-folate supplements. They
identiﬁed three trials (2959 women), and no effect on PTB
(RR 1.01, 95% CI 0.73–1.38).
Vitamin A supplementationwas evaluated in two reviews. Both
compared vitamin A supplementation to placebo. McCauleyPlease cite this article in press as: A. Matei, et al., Primary and seconda
ongoing randomized controlled trials, Eur J Obstet Gynecol (2019), httpet al. (2015) conducted a Cochrane review on the effects of
Vitamin A on obstetrical outcomes. They compared vitamin A
alone versus placebo (4 trials, 40137 women, RR 0.98, 95% CI
0.94–1.01), vitamin A versus a multivitamin lacking vitamin A
(0 trials), and a vitamin A containing multivitamin versus a
multivitaminwithout (1 trial,136 women, RR 0.39, 95% CI 0.08–
1.93, high quality evidence).Thorne-Lyman & Fawzi (2012b)
was a non-Cochrane review that compared vitamin A alone
versus placebo (7 trials, 19799 women) and found no effect on
PTB risk (RR 0.99, 95% CI 0.88–1.10).
Vitamin D supplementation, alone or in conjunction with
other supplements, was evaluated in three reviews, and none
showed signiﬁcance in terms of risk of PTB Thorne-Lyman &
Fawzi (2012a) evaluated vitamin D supplementation at any
dose, compared to placebo, among low risk women (2 trials,
529 women). There was no effect on PTB (RR 0.77, 95% CI
0.35–1.66). Pérez-López et al. (2015) compared vitamin D,
alone or in combination with calcium and vitamin supple-
ments, to placebo, no supplement, or supplements without
vitamin D (3 trials, 384 women) and also found no effect on
PTB (RR 1.26, 95% CI 0.60–2.63). De-Regil et al. (2012) also
evaluated vitamin D (at any dose) alone or in combination
with another supplement, compared to placebo or no
supplements. They identiﬁed 6 trials (1023 women) butry prevention of preterm birth: a review of systematic reviews and
s://doi.org/10.1016/j.ejogrb.2018.12.022
Fig. 3. Effect estimates of secondary prevention intervention on preterm birth.
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(De-Regil et al., 2016) three trials (477 women) compared
vitamin D alone compared to placebo. There was an overall
decreased risk of PTB (RR 0.36, 95% CI 0.14-0.93). Interesting-
ly, women who received vitamin D with calcium had an
increased risk of PTB compared to women who received no
supplementation or placebo (3 trials, 798 women, RR 1.57,
95% CI 1.01–2.43). The authors noted that the risk of bias inPlease cite this article in press as: A. Matei, et al., Primary and seconda
ongoing randomized controlled trials, Eur J Obstet Gynecol (2019), httpmost trials is unclear and many trials were at high risk of bias
for blinding at attrition rates.
Vitamin E supplementation was not shown to reduce PTB risk
in one review (Rumbold et al., 2015; 11 trials, 20565 women,
RR 0.98, 95% CI 0.88–1.09).
Salam Rehana et al. (2015) aimed to evaluate the effect of
pyridoxine on PTB and did not ﬁnd any trials that met
inclusion criteria.ry prevention of preterm birth: a review of systematic reviews and
s://doi.org/10.1016/j.ejogrb.2018.12.022
Fig. 3. (Continued)
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Chaffee and King (2012) compared zinc supplementation to
placebo/no intervention (16 trials, 7818 women) and showed
a reduction in PTB (RR 0.86, 95% CI 0.75 to 0.99, low-quality
evidence). Ota et al. (2015a) compared zinc supplementation
to placebo or no intervention or non-zinc intervention and
also showed a reduction in PTB based on 16 trials including
7637 women (RR 0.86, 95% CI 0.76 to 0.97, moderate-quality
evidence).
Fish oil, marine oil, and omega-3 fatty acids was evaluated in
six reviews. Kar et al. (2016) compared omega-3 fatty acid
supplementation with an unspeciﬁed control group in 9 trials
and 5980 women and found a reduction in PTB (RR 0.83, 95%Please cite this article in press as: A. Matei, et al., Primary and seconda
ongoing randomized controlled trials, Eur J Obstet Gynecol (2019), httpCI 0.70 to 0.98). Salvig and Lamont (2011) evaluated long
chain n-3 fatty acid supplementation compared to placebo or
no supplementation (4 trials, 1187 women) and also found a
reduction in PTB (RR 0.61, 95% CI 0.40 to 0.93). The remaining
four reviews did not show a statistically signiﬁcant effect on
PTB risk but Chen et al. (2016) found a reduction in PTB < 34
weeks (RR 0.78, 95% CI 0.64 to 0.95) with ﬁsh oil
supplementation.
Dietary supplementation with multiple micronutrients was
evaluated in four reviews. Suchdev et al. (2015) evaluated
micronutrients in powder forms for fortiﬁcation of foods
compared to a wide range of controls (no intervention, placebo,
iron and folate supplements, iron alone, folate alone, or otherry prevention of preterm birth: a review of systematic reviews and
s://doi.org/10.1016/j.ejogrb.2018.12.022
Fig. 3. (Continued)
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reported on their outcomes of interest, including preterm birth.
Haider and Bhutta (2015), compared 3 or more micronutrients
including iron and folic acid compared to placebo or no
supplementation (1 trial, unspeciﬁed number of women), and
compared to iron with or without folic acid (15 trials,
unspeciﬁed number of women). Neither comparison showed
a signiﬁcant effect on PTB. Two non-Cochrane reviews were
identiﬁed. Ramakrishnan et al. (2012) found no effect on
preterm birth with supplementation with 5 or more micro-
nutrients compared to 3 or less micronutrients including ironPlease cite this article in press as: A. Matei, et al., Primary and seconda
ongoing randomized controlled trials, Eur J Obstet Gynecol (2019), httpand folic acid (9 trials, 45909 women, RR 0.99, 95% CI 0.96–
1.03), while Fall et al., (2009) compared “multiple micro-
nutrients” to an unspeciﬁed placebo and also found a
nonsigniﬁcant effect on PTB (12 trials, unspeciﬁed number of
women, RR 1.00, 95% CI 0.93–1.09).
Nutritional education compared to no nutritional education
or a different form of consultation was assessed in one
systematic review (Ota et al., 2015b). This included two trials
and 449 women. Risk of PTB was lower in women who
received nutrional education (RR 0.46, 95% CI 0.21–0.98, low
quality evidence). The same review also evaluated highry prevention of preterm birth: a review of systematic reviews and
s://doi.org/10.1016/j.ejogrb.2018.12.022
Fig. 3. (Continued)
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during pregnancy and found no effect on PTB. There was
insufﬁcient data for comparisons involving balanced protein-
energy intake and isocaloric protein supplementation.
Dietary advice was also evaluated by Thangaratinam et al.
(2012). Compared to standard care, dietary advice was
associated with a reduced risk of PTB (4 trials, 1474 women,
RR 0.68, 95% CI 0.48–0.96).
Probiotics were evaluated in one review by Othman et al.
(2007). Routine probiotics to prevent or treat urogenital
infections in all pregnant women did not show an effect on
PTB risk (1 trial, 238 women, RR 3.95, 95% CI 0.36–42.91).
5 Psychosocial interventions: One review (Dennis & Kingston,
2008) compared telephone support by a lay person or health
care professional with no intervention and found no effect on
PTB (14 trials, 8037 women, RR 0.87, 95% CI 0.75–1.01).
6 Screening with and without treatment: Repeat digital cervical
examinations (Alexander et al., 2010; 2 trials, 7163 women)
and universal screening for thyroid disease (Spencer et al.,Please cite this article in press as: A. Matei, et al., Primary and seconda
ongoing randomized controlled trials, Eur J Obstet Gynecol (2019), http2015; 1 trial, 4516 women) were shown to have no effect on
PTB. Two reviews set out to evaluate universal screening for
bacterial vaginosis (Nygren et al., 2008) and PTB scoring
systems (Davey et al., 2013) but they found no eligble studies.
Sangkomkamhang et al. (2015) evaluated routine screening
for lower genital tract infections in pregnancy by wet mount,
gram stain or vaginal culture compared to routine antenatal
care without screening. They included a single trial (4155
women) and found a reduction in PTB (RR 0.55, 95% CI 0.41 to
0.75, moderate quality evidence).
7 Special tests or investigations: Two reviews evaluated antena-
tal care with routine Doppler sonography (Alﬁrevic et al.,
2015; 4 trials, 12162 women), or routine tests of placental
function with results available to clinician (Heazell et al.,
2015; 1 trial, 118 women) and found no effect on PTB risk.
II Secondary outcomes–primary preterm birth prevention:
Secondary outcomes were infrequently reported. The
most commonly reported were perinatal, fetal and neonatal
mortality.ry prevention of preterm birth: a review of systematic reviews and
s://doi.org/10.1016/j.ejogrb.2018.12.022
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different with the following primary prevention interventions:
omega 3 (Kar et al., 2016; Saccone & Berghella, 2015), marine oil
(Makrides et al., 2006), vitamin D (De-Regil et al., 2012), vitamin
A (McCauley et al., 2015; Thorne-Lyman & Fawzi, 2012),
vitamins B or C (Dror et al., 2012), vitamin E (Rumbold et al.,
2012), antioxidants (Rumbold et al., 2008), zinc (Ota et al.,
2015a), iron supplementation (Cantor et al., 2015), group
antenatal care (Catling et al., 2015), aerobic exercise (Kramer
et al., 2009), folic acid supplementation (Lassi Zohra et al.,
2013), nutritional education and supplementation for energy or
protein (Ota et al., 2015b) or multiple vitamins and minerals
(Pena-Rosas et al., 2015; Ramakrishnan et al., 2012), and routine
antibiotic prophylaxis (Thinkhamrop et al., 2015).When multi-
ple micronutrients with iron and folic acid were compared to
folic acid and iron alone there was a reduction in fetal mortality
with a RR 0.91, 95% CI 0.85–0.98, but there was no difference
when the control group included placebo or no treatment
(Haider et al., 2015). Routine calcium supplementation did not
affect mortality in three reviews (Buppasiri et al., 2015;
Hofmeyr et al., 2014; Al Dorazi et al., 2014), however one
(Imdad, 2011) found a reduction in neonatal mortality (RR 0.70,
95% CI 0.56 to 0.88). One review of routine Doppler sonography
found reduced neonatal mortality (Alﬁrevic et al., 2015; RR 0.34,
95% CI 0.12–0.95).
The other secondary outcomes were assessed in few reviews,
and where they were reported they were largely not different.
Low birth weight was reduced with certain micronutrients
supplementation (Haider et al., 2015), screening and treatment
for lower genital tract infections (Sangkomkamhang et al.,
2015), vitamin D (Thorne-Lyman et al., 2012), and ﬁsh oil
supplements (Chen et al., 2012).
Maternal outcomes were very infrequently reported. Maternal
satisfaction was reported in only three reviews. Women in
group antenatal care were more satisﬁed than women receiving
conventional care (Catling et al., 2015). There was a signiﬁcant
reduction in maternal deaths and ICU admissions with calcium
supplemtation in women regardless of risk factors and in
women with low intake (Hofmeyr et al., 2014). Calcium
supplementation in all pregnant women was also found to
reduce maternal death in another review (Imdad, 2011).
The ﬁndings of the individual reviews are shown in Supple-
mentary material.
III Secondary prevention of preterm birth
There were 83 systematic reviews of secondary prevention
strategies (Fig. 3).
1 Devices: Urquhart et al. (2015) compared home monitoring
activity versus standard care among women considered to
be at risk of PTB. The risk of PTB was not statistically
different between the two groups (8 trials, 4834 women,
RR0.85, 95% CI 0.72–1.01). Sealing procedures for women
with premature rupture of membranes was shown to reduce
PTB (2 trials, 124 women, RR 0.48, 95% CI 0.38 to 0.68) in one
review (Crowley et al., 2016) however the number of
participants was small.
2 Lifestyle and behavioural changes: Two reviews evaluated bed
rest at home or in the hospital for women at high risk of PTB
and found no signiﬁcant effect. (Sosa et al., 2015; 1 trial,1266
women; and Crowther et al. 2010; 7 trials, 713 women).
3 Anticoagulant and antiplatelets agents: Eleven reviews
evaluated the effect of aspirin, other COX inhibitors or
heparin. One review (Meher et al., 2016) was an IPD meta-
analysis on the effects of using one or more antiplatelet
agents (low dose aspirin or another agent) to prevent
preeclampsia. They did not report on PTB < 37 weeks,
however reported on a reduction in PTB < 34 weeks (26Please cite this article in press as: A. Matei, et al., Primary and seconda
ongoing randomized controlled trials, Eur J Obstet Gynecol (2019), httptrials, 31272 women, RR 0.90, 95% CI 0.83 to 0.98). However,
subgroup analyses of women randomized to start anti-
platelets before 16 weeks gestation (19 trials, 9155 women,
RR 0.90, 95% CI 0.88–1.04) or after 16 weeks (25 trials, 22117
women, RR 0.82, 95% CI 0.82–1.00) showed no statistically
signiﬁcant effect on PTB.
Low dose aspirin (LDASA) alone or in combination with
dipyridamole was found to reduce risk of PTB among women
at risk for preeclampsia in eight systematic reviews. Askie
et al. (2007) was an IPD meta-analysis that compared LDASA
with or without dipyridamole to placebo or no treatment
among women at risk of preeclampsia (26 trials, 31316
women). There was a reduction in risk of PTB < 37 weeks (RR
0.93, 95% CI 0.89-0.98) and <34 weeks (RR 0.90, 95% CI 0.83-
0.98), but not <28 weeks (RR 0.87, 95% CI 0.75–1.02). They did
not assess antiplatelets given at a speciﬁc gestational,
however 59% of women were randomized and received
therapy at < = 20 weeks gestation. A subsequent subgroup
analysis of this IPD by van Vliet et al. (2017) showed a similar
trend in risk reduction of spontaneous PTB < 37 weeks (17
trials, 28797 women, RR 0.93, 95% CI 0.86-0.996), PTB < 34
weeks (RR 0.86, 95% CI 0.76–0.99). The risk of PTB < 28 weeks
was not signiﬁcantly reduced (RR 0.81, 95% CI 0.59–1.12).
Roberge et al. (2012) evaluated the administration of LDASA
with or without dipyridamole at 16 weeks gestation or less,
compared to placebo or no treatment and identiﬁed a
decreased risk of PTB < 37 weeks (5 trials, 556 women, RR
0.11, 95% CI 0.04–0.33). Roberge et al., (2013) compared
administration of LDASA +/- dipyridamole before or after 16
weeks gestation. There was an overall reduction in risk of
PTB (22 trials, 11302 women, RR 0.81, 95% CI 0.71-0.92), but
there was a greater reduction with administration at or
before 16 weeks (6 trials, 904 women, RR 0.35, 95% CI 0.22–
0.57) compared to after 16 weeks (16 trials, 10398 women,
RR 0.90, 95% CI 0.83–0.97).
Cristina Rossi et al., (2009) observed a reduction in PTB with
LDASA alone compared to placebo administered to women
at high risk for pre-eclampsia (6 studies, 9966 women, OR
0.85, 95% CI 0.77–0.94). These ﬁndings were supported by
subsequent reviews (Henderson et al., 2014; 10 studies,
11779 women, RR 0.86, 95% CI 0.76–0.98; Xu et al., 2015; 29
trials, 21403 women, OR 0.81, 95% CI 0.75–0.88; and Yao
et al., 2015; 5 trials, 860 women with treatment started prior
to 16 weeks gestation, RR 0.20, 95% CI 0.08–0.48). Of note,
Cristina Rossi et al., (2009) also assessed vitamin C and E
versus placebo in reducing PTB among women at risk of
preeclampsia and found no effect.
Low molecular weight heparin and aspirin did not reduce
risk of PTB when compared to aspirin alone among women
with inherited thrombophilia (4 trials, 222 women, RR 0.99
(0.4–2.08) (Areia et al., 2016).
A Cochrane review (Khanprakob et al., 2012) identiﬁed one
trial (98 women) randomized to a COX inhibitors (refecoxib)
compared to placebo and identiﬁed an increased risk of PTB
in the comparison group (RR 1.65, 95% CI 1.11–2.45).
4 Antibiotics: The use of antibiotics was evaluated in nine
reviews.
Interventions that did not affect the preterm birth rate
included: antibiotics for premature rupture of membranes
(Kenyon et al., 2013; 3 trials, 4931 women), any treatment
for bacterial vaginosis or trichomoniasis (Okun et al., 2005,
11 trials, 6052 women; Blocklehurst et al., 2013, 13 trials,
6491 women), nitrofurantoin prophylaxis for recurrent
urinary tract infections (Schneeberger et al., 2015); 1 trial,
147 women), and prophylactic prenatal antibiotics (Think-
hamrop et al. 2015), 2 trials, 758 women).ry prevention of preterm birth: a review of systematic reviews and
s://doi.org/10.1016/j.ejogrb.2018.12.022
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found that clindamycin for treatment of bacterial vaginosis
reduced PTB risk (RR 0.60, 95% CI 0.42 to 0.86), while
metronidazole for trichomoniasis was associated with an
increased risk in one review (Gülmezoglu et al., 2011; 1 trial,
604 women, RR 1.78, 95% CI 1.19–2.66). Treatment of vaginal
candidiasis was associated with a reduction in PTB risk in
one review (Roberts et al., 2015; 2 trials, 685 women, RR
0.36, 95% CI 0.17-0.75).
5 Progesterone: Ten reviews evaluated progesterone supple-
mentation in women with high risk pregnancies.
a Women with singleton pregnancies and previous preterm
bith: Progesterone (oral or intramuscular) was an
effective PTB prevention strategy in women with single-
ton gestations and with previous preterm birth in two
reviews. Likis et al. (2012) included 5 trials and 372
women and showed a RR 0.78 (95% CI 0.68 to 0.88) among
women on any form of progesterone compared to an
unspeciﬁed control. Dodd et al., (2013) included 10 trials,
1750 women, and found a RR 0.55 (95% CI 0.42 to 0.74)
with progesterone supplementation compared to placebo
or no treatment. One review (Saccone et al., 2016)
reported that daily vaginal progesterone (either supposi-
tory or gel) is a better alternative to weekly intramuscular
17α-hydroxyprogesterone caproate (17-OHPC) in pre-
venting PTB < 34 weeks (3 trials, 680 women, RR 0.71,
95% CI 0.53-0.95, low quality evidence) and PTB < 32
weeks (RR 0.62, 95% CI 0.40-0.94, low quality evidence).
b Multiple gestations: Progesterone supplementation for
unselected women with multiple pregnancies did not
reduce PTB in three reviews: Likis et al., 2012; 4 trials,
unspeciﬁed number of women, RR 1.02, 95% CI 0.87–1.17;
Dodd et al., 2013; 8 trials, 2674 women, RR 1.04, 95% CI
0.95-1.14. Schuit et al. (2015) was an IPD meta-analysis on
twin pregnancies that deﬁned gestational age at delivery
to include intrauterine fetal demise. Neither vaginal
progesterone (7 trials, 929 women, RR 0.97, 95% CI0.85-
1.10) nor intramuscular progesterone (6 trials, 2021
women, RR 1.10, 95% CI 0.94–1.20) reduced PTB when
compared to placebo or no treatment.
c Women in preterm labour: Progesterone for women in
preterm labour was found to be effective in one review
(Likis et al., 2012; 5 trials, unspeciﬁed number of women,
RR 0.62, 95% CI 0.47 to 0.79) but supplementation for
women in threatened preterm labour (and not in active
PTL) did not show a beneﬁt in another review (Dodd et al.,
2013; 2 trials, 223 women, RR 0.51, 95% CI 0.20–1.31).
d Sonographically short cervix: Progesterone for women
with sonographically short cervix did not reduce risk of
PTB < 37 weeks in four reviews (Dodd et al., 2013; 3 trials,
1303 women, RR 0.97, 95% CI 0.82–1.15; Conde-Agudelo
et al., 2013; 4 trials, 158 women, RR 0.84, 95% CI 0.61–1.14;
Romero et al., 2016, 5 trials, 723 women, RR 0.89, 95% CI
0.74–1.08). However, the IPD meta-analysis by Romero
et al. (2016) found a signiﬁcant reduction in PTB  34
weeks or fetal death (5 trials, 974 women, RR 0.66, 95% CI
0.52-0.83), PTB < 34 weeks only (RR 0.60, 95% CI 0.44-
0.82) and spontaneous PTB < 34 weeks (RR 0.63, 95% CI
0.44-0.88), and at earlier gestational ages (PTB < 32
weeks, RR 0.56, 95% CI 0.38-0.82; and PTB < 28 weeks,
RR 0.51, 95% CI 0.31-0.85). One review also compared
progesterone to cerclage in women with short cervix
(Conde-Agudelo et al., 2013) and found no difference
(unspeciﬁced number of trials, RR 1.20, 95% CI 0.84–1.72).
e Any risk factors for PTB: Progesterone in women with any
risk factors for PTB was evaluated in three reviewsPlease cite this article in press as: A. Matei, et al., Primary and seconda
ongoing randomized controlled trials, Eur J Obstet Gynecol (2019), http(Coomarasamy et al., 2006; Dodd et al., 2013; Sotiriadis
et al., 2012). Only one found a reduction in PTB risk
(Coomarasamy et al., 2006; 8 trials, unspeciﬁed number of
women) with a RR 0.42 (95% CI 0.31 to 0.57). One
(Sotiriadis et al., 2012) did not identify any applicable
trials.
6 Other medications: L-arginine was evaluated in one review.
Dorniak-Wall et al. (2014) found a reduction in PTB risk (RR
0.48, 95% CI 0.28 to 0.81) in women at risk for preeclampsia
treated with L-arginine versus placebo (1 trial, 672 women).
Levothyroxine was found to reduce risk of PTB among
women with thyroid disease when compared to no
treatment (Reid et al., 2013; 1 trial, 115 women; RR 0.28,
95% CI 0.10 to 0.80). Oral betamimetics in twin pregnancies
was not found to reduce PTB risk when compared to placebo
or other interventions to prevent PTB (Yamasmit et al., 2015;
4 trials, 276 women, RR 0.85, 95% CI 0.65–1.1).
7 Models of health care: Two reviews evaluated specialized
models of antenatal care among women at high risk for PTB.
Dodd et al. (2015) set out to evaluate specialized antenatal
care for women with twin gestations and did not indentify
any eligible studies that assessed PTB risk, although they did
report on neonatal outcomes including an increased risk of
NICU admission (RR 1.43, 95% CI 1.02–2.00) and C-section
rate (RR 1.38, 95% CI 1.06–1.81). Whitworth et al., (2011)
included 3 trials and 3400 women and compared specialized
care to standard care in women with singleton pregnancies
at risk for PTB. There was no difference detected in risk for
PTB (RR 0.87, 95% CI 0.69–1.08).
8 Nutritional supplements: Antioxidants for women at risk of
preeclampsia (Rumbold et al., 2008; 3 trials, 3131 women,
RR 1.09, 95% CI 0.97–1.22), long chain polyunsaturated fatty
acids for women at risk of PTB (Horvath et al., 2007; 4 trials,
523 women, RR 0.82, 95% CI 0.60–1.12), omega-3 for women
with previous PTB (Saccone et al., 2015a; 2 women, 1080
women, RR 0.81, 95% CI 0.59–1.21), calcium in women with
low intake (Hofmeyr et al., 2015; 7 trials, 10242 women, RR
0.81, 95% CI 0.64–1.02), selenium (Reid et al., 2013; 1 trial,
169 women, RR 0.96, 95% CI 0.20–4.61), and vitamin A
among HIV positive women (Wiysonge et al., 2011, 3 trials,
2110 women, RR 0.88, 95% CI 0.65–1.19) did not have effects
on PTB in high-risk women. Calcium supplementation was
found to reduce risk of PTB in women at risk of hypertensive
disorders in one review (Hofmeyr et al., 2015, 4 trials, 568
women, RR 0.45, 95% CI 0.24 to 0.83).
9 Psychosocial interventions: One review found that smoking
cessation or relapse prevention programs for high risk
women resulted in a reduced risk of PTB when compared to
usual care, less intensive care or alternative care, based on 14
reviews and 7852 women (Chamberlain et al., 2013), RR 0.82
(95% CI 0.71 to 0.96). There was no signiﬁcant effect on PTB
with social support for women at high risk of PTB (Hodnett
et al., 2010; 17 trials, 12,264 women, RR 0.92, 95% CI 0.83–
1.01), relaxation therapy for women in preterm labour
(Khianman et al., 2012; 1 trial, 120 women, RR 0.95, 95% CI
0.57–1.59), or “any psychosocial intervention” for teenage
pregnant women (Sukhato et al., 2015; 4 trials, 684 women,
RR 0.67, 95% CI 0.42–1.05).
10 Screening +/- treatment: Berghella et al., (2011) showed that
cervical length screening in singleton gestations with
history of preterm birth, and placement of cerclage in
women with short cervix resulted in a PTB reduction
comparable to cerclage placement based on history only (4
trials, 467 women, RR 0.97, 95% CI 0.73–1.29).
11 Cerclage and pessary: Women at risk of preterm birth who
had a cerclage had a lower risk of preterm birth than womenry prevention of preterm birth: a review of systematic reviews and
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RR 0.80, 95% CI 0.69-0.95). Three reviews evaluated two
speciﬁc subpopulations of women. An IPD meta-analysis by
Berghella et al. (2010) evaluated the effectiveness of cerclage
for women with singleton pregnancies and short cervix
<25 mm on midtrimester ultrasound and found a decreased
risk of PTB (4 trials, 552 women, RR 0.79, 95% CI 0.65-0.95). A
non-Cochrane review by Berghella et al. (2011b) looked at
cerclage for asymptomatic women with singleton gestation,
history of preterm birth, and short midtrimester cervical
length on ultrasound and found a decreased risk of PTB as
well (5 trials, 874 women, RR 0.70, 95% CI 0.58-0.83). These
results were supported by Conde-Agudelo et al. (2013),
whose population also included singleton pregnancies with
short midtrimester ultrasound and history of preterm birth
and who found a RR 0.70, 95% CI 0.58-0.83, across 5 trials
and 504 women.
Two reviews investigated cerclage for multiple pregnancies
and both identiﬁed a nonsigniﬁcant effect on PTB (Rafael et al.,
2014; 5 trials, 128 women, RR 1.12, 95% CI 0.89–1.43; and Liu
et al. 2013; 5 trials, 310 women, RR 1.01, 95% CI 0.77–1.33).
One Cochrane review assessed cervical pessary versus
expectant management in singleton gestations with short
cervix of 25 mm or less, and found a reduction in PTB (Abdel-
Aleem et al., 2013; 1 trial, 385 women; RR 0.36, 95% CI 0.27
to 0.49).
12 Treatment of periodontal disease: Two out of the nine reviews
that evaluated this intervention showed a signiﬁcant
reduction in PTB in women with periodontal disease who
receive treatment (George et al., 2011: 10 trial, 5496 women,
RR 0.65, 95% CI 0.45 to 0.93; Uppal et al., 2010; 10 trials, 6142
women, RR 0.59, 95% CI 0.40 to 0.88).
But a majority of reviews found no effect on PTB for this
intervention. Schwendicke et al. (2015) evaluated subgingival
scaling and root planning with or without adjunct antibiotics
for women with periodontal disease (5 trials, unspeciﬁed
number of women, OR 0.79, 95% CI 0.57–1.10). Boutin et al.
(2013) also evaluated periodontal treatment for women with
periodontal disease but included a wide range of control
groups including no care, hygiene education, or supragingival
treatment (12 trials, 7018, RR 0.89, 95% CI 0.73–1.08).
Chambrone et al. (2011) compared scaling and root planning
with or without antibiotics for plaque induced ginigivitis to no
treatment, supragingival debridement and tooth polishing (11
trials, 5752 women, RR 0.88, 95% CI 0.72–1.09). Fogacci et al.
(2011) compared treatment ofdestructive periodontal disease
or periodontitis to no treatment or dental plaque instruction,
prophylaxis, or supragingival scaling. Risk of PTB was reported
controlled for multiparity on the basis that it was the largest
number of trials for this outcome (8 trials, 5270 women, RR
0.92, 95% CI 0.72–1.17). Kim et al. (2012) compared scaling and
root planning to placebo or no treatment (11 trials, 5655
women, RR 0.81, 95% CI 0.64–1.01). An earlier comparison of
scaling and root planning to placebo or no treatment
conducted by Polyzos et al. (2010) identiﬁed 11 trials, 6558
women, and RR 0.93, 95% CI 0.79-1.10. Rosa et al. (2012) used
more stringent inclusion criteria and compared periodontal
treatment to standard care for women with singleton
gestation at 22 weeks of less and stringent criteria for
deﬁniting periodontal disease. They identiﬁed 13 trials, 6988
women, and no effect on PTB (RR 0.90, 95%CI 0.68–1.19).
IV Secondary outcomes–secondary prevention:
Perinatal, fetal or neonatal mortality were generally not different
with the following secondary prevention interventions: cervical
cerclage in high risk women (Alﬁrevic et al., 2012; Berghella and
MacKeen, 2011a and b; Conde-Agudelo et al., 2013, Jorgensen et al.,Please cite this article in press as: A. Matei, et al., Primary and seconda
ongoing randomized controlled trials, Eur J Obstet Gynecol (2019), http2007, Rafael et al., 2014, Saccone et al. 2015b; Meher et al., 2017),
antiplatelet agents in women at risk for preeclampsia (Askie et al,
2007; Roberge et al., 2013; Xu et al., 2015; Cristina et al., 2009),
treatment for vaginitis (Brocklehurst et al., 2013; Lamont et al.,
2011; Okun et al., 2005), routine prophylactic antibiotics (Think-
hamrop et al., 2015), antibiotics for premature rupture of
membranes (Kenyon et al., 2013), planned early delivery for
women with premature rupture of membranes (Buchanan et al.,
2010), psychosocial interventions for smoking cessation (Cham-
berlain et al., 2013), nicotine replacement for smoking cessation
(Coleman et al., 2011), antenatal bedrest for multiple gestation
(Crowther et al., 2010), specialized antenatal care in women with
multiple gestation (Dodd et al., 2015) and in women at risk of
having a preterm or growth restricted baby (Hodnett et al., 2010;
Whitworth et al., 2011), periodontal treatment for women with
periodontal disease (George et al., 2011; Polyzos et al., 2010;
Schwendicke et al., 2015), calcium supplementation (Hofmeyr
etal.,2014), longchainpolyunsaturatedfattyacidsupplementation
(Horvath et al., 2007) and omega 3 (Saccone & Berghella, 2015a),
vitamin A for HIV positive women (Wiysonge et al., 2011), and
home uterine monitoring (Urquhart et al., 2015),
Progesterone in high risk women did not have a signiﬁcant effect
on perinatal mortality in multiple reviews (Conde-Agudelo et al.,
2013; Dodd et al., 2013; Likis et al., 2012; Romero et al., 2012, and
2016; Schuit et al., 2015; Sotiriadis et al., 2012; Combs et al., 2012),
except inwomenwith a singletonpregnancyand historyof PTB. In
this subpopulation, Dodd et al., (2013) showed decreased
perinatal mortality (RR 0.50, 95% CI 0.33 to 0.75), neonatal
mortality (RR 0.45, 95% CI 0.27 to 0.76), low birth weight (RR 0.58,
95% CI 0.42 to 0.79), and NICU admission (RR 0.24, 95% CI 0.14 to
0.40). Likis et al. (2012) also showed decreased neonatal mortality
with progesterone in a subpopulation of women with previous
preterm birth (RR 0.58, 95% CI 0.27 to 0.98), asymptomatic short
cervix (RR 0.40, 95% CI 0.09 to 0.91), and women with preterm
labour, butnot in multiple gestations. Riskof low birthweightwas
also decreased in women with previous PTB (RR 0.66, 95%CI 0.51
to 0.87). There was a reduced risk of NICU admission with
progesterone in women with short cervix and singleton
pregnancies (Romero et al., 2016), women with singleton
gestation, short cervix and history of preterm birth (Conde-
Agudeloetal.,2013),andareducedrisk withvaginal progesterone
compared to intramuscular progesterone in asymptomatic
singletons with history of PTB (Saccone et al., 2016).
Sealing procedures for women with premature rupture of
membranes was shown to reduce neonatal mortality (RR 0.38,
95% CI 0.19 to 0.75) in one review (Crowley et al., 2016).
The other secondary outcomes were assessed in few reviews
and most interventions had no effect. Psychosocial programs
(Chamberlain et al., 2013) and nicotine replacement therapy
(Coleman et al., 2011) for smoking cessation were found to
reduce risk of low birth weight. Periodontal treatment was also
found to reduce LBW in one review (George et al. 2011).
Data for maternal outcomes were rarely available. There was no
difference in maternal satisfaction with vaginal progesterone
compared to control (Dodd et al., 2013) and in women with
multiple gestation receiving specialized antenatal care (Dodd
et al., 2015).
Discussion
Key ﬁndings
This review of reviews aimed to systematically assess existing
literature regarding effectiveness and safety of interventions to
prevent PTB.In total, 112 reviews were included.ry prevention of preterm birth: a review of systematic reviews and
s://doi.org/10.1016/j.ejogrb.2018.12.022
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interventions on risk of PTB. Positive effects were found for
lifestyle and behavioural changes, including diet and exercise;
nutritional supplements, including calcium and zinc supplemen-
tation; nutritional education; screening for lower genital tract
infections. However, there were no or minimal data available for
most of our secondary outcomes.
There were 83 systematic reviews of secondary prevention
interventions. Positive effects were found for low dose aspirin
among women at risk of preeclampsia; clindamycin for treatment
of bacterial vaginosis and treatment of vaginal candidiasis;
progesterone in women with prior spontaneous PTB and in those
with short midtrimester cervical length; L-arginine in women at
risk for preeclampsia; levothyroxine among women with thyroid
disease; calcium supplementation in women at risk of hyperten-
sive disorders; smoking cessation; cervical length screening in
high-risk singleton gestations; cervical pessary in singleton
gestations with short cervix; and treatment of periodontal disease.
COX inhibitors and metronidazole for trichomoniasis seem to be
associated with an increased risk of PTB.
Our results may be inﬂuenced by the methodological quality of
the included reviews and RCTs. Interventions that may have an
effect on PTB but are used for other conditions could potentially
have been missed, however we used a broad search strategy to
minimize this risk. The major shortcoming of a review of reviews is
the loss of more detailed information by qualitatively aggregating
information. For example, women at risk of PTB were deﬁned
precisely in some reviews, but not in others.
The prevention of prematurity is a rapidly evolving maternal
and child health topic. Therefore, summarizing evidence of this
topic is an important priority.
This article is, to our knowledge, the ﬁrst review of reviews on
primary and secondary prevention of PTB that has considered all
forms of systematic reviews as well as a review of planned and
ongoing trials. The possible effects of a diverse range of interventions
for primary and secondary prevention of PTB have been evaluated in
severalsystematic reviews of RCTs.Altough there isa large numberof
reviews, few interventions have been deﬁnitvely demonstrated to be
safe and effective. For several of the interventions evaluated, there
was insufﬁcient evidence to assess whether the intervention was
effective or not. There is little high-quality evidence for most of the
interventions studied, which should be taken into account when
making magenement decisions.
The difﬁculty in interpreting the results of this review
highlights the importance of having a speciﬁc population to be
studied in trials on PTB, such as those at risk of PTB, and conducting
RCTs in comparing interventions. There should be an agreed-upon
set of clearly-deﬁned and measurable outcomes, including
maternal secondary outcomes such as maternal deths, satisfaction,
admission to intensive care unit, in future PTB intervention trials,
so that outcomes of trials can be easily meta-analysed The vast
majority of the trials in included reviews were small; review
authors often emphasized the need for larger, well-designed RCTs.
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